Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, United States.
Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, United States.
Biochemistry. 2022 May 3;61(9):795-803. doi: 10.1021/acs.biochem.1c00813. Epub 2022 Apr 3.
Titanocene dichloride (TDC) is an anticancer agent that delivers Ti(IV) into each of the two Fe(III) binding sites of bilobal human serum transferrin (Tf). This protein has been implicated in the selective transport of Ti(IV) to cells. How Ti(IV) might be released from the Tf Fe(III) binding site has remained a question, and crystal structures have raised issues about lobe occupancy and lobe closure in Ti(IV)-loaded Tf, compared with the Fe(III)-loaded form. Here, inductively coupled plasma optical emission spectroscopy reveals that Tf can stabilize toward hydrolytic precipitation more than 2 equiv of Ti, implying superstoichiometric binding beyond the two Fe(III) binding sites. Further studies support the inability of TDC to induce a complete lobe closure of Tf. Fluorescence data for TDC binding at low equivalents of TDC support an initial protein conformational change and lobe closure upon Ti binding, whereas data at higher equivalents support an open lobe configuration. Spectroscopic titration reveals less intense protein-metal electronic transitions as TDC equivalents are increased. Denaturing urea-PAGE gels and small angle X-ray scattering studies support an open lobe conformation. The concentrations of bicarbonate used in some earlier studies are demonstrated here to cause a pH change over time, which may contribute to variation in the apparent molar absorptivity associated with Ti(IV) binding in the Fe binding site. Finally, Fe(III)-bound holo-Tf still stabilizes TDC toward hydrolytic precipitation, a finding that underscores the importance of the interactions of Tf and TDC outside the Fe(III) binding site and suggests possible new pathways of Ti introduction to cells.
二氯二茂钛(TDC)是一种抗癌药物,可将 Ti(IV) 递送至人血清转铁蛋白(Tf)的两个 Fe(III) 结合位点中的每一个。该蛋白已被牵连到 Ti(IV) 向细胞的选择性转运中。Ti(IV) 如何从 Tf Fe(III) 结合位点释放仍然是一个问题,与 Fe(III) 负载形式相比,晶体结构提出了关于 Ti(IV) 负载 Tf 中叶瓣占据和叶瓣闭合的问题。在这里,电感耦合等离子体发射光谱法表明,Tf 可以稳定地水解沉淀超过 2 当量的 Ti,这意味着超化学计量的结合超过了两个 Fe(III) 结合位点。进一步的研究支持 TDC 不能诱导 Tf 的完全叶瓣闭合。在 TDC 的低当量处的 TDC 结合的荧光数据支持 Ti 结合时初始蛋白质构象变化和叶瓣闭合,而在更高当量时的数据支持开放叶瓣构象。光谱滴定显示,随着 TDC 当量的增加,蛋白质-金属电子跃迁的强度降低。变性脲-PAGE 凝胶和小角 X 射线散射研究支持开放叶瓣构象。在一些早期研究中使用的碳酸氢盐浓度在这里被证明会随着时间的推移导致 pH 变化,这可能导致与 Fe 结合位点中 Ti(IV) 结合相关的表观摩尔吸光率的变化。最后,Fe(III) 结合的全 Tf 仍然稳定 TDC 以防止水解沉淀,这一发现强调了 Tf 和 TDC 在 Fe(III) 结合位点之外的相互作用的重要性,并提出了 Ti 引入细胞的可能新途径。